Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

British Journal of Cancer

Volumn 92, Issue 4, 2005, Pages 634-638

  Berruti, A ^a   Bitossi, R ^a   Gorzegno, G ^a   Bottini, A ^b   Generali, D ^b   Milani, M ^b   Katsaros, D ^c   Rigault De La Longrais, I A ^c   Bellino, R ^c   Donadio, M ^d   Ardine, M ^d   Bertetto, O ^d   Danese, S ^c   Sarobba, M G ^e   Farris, A ^e   Lorusso, V ^f   Dogliotti, L ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c Azienda Ospedaliera Materno Infantile OIRM SAnna   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f Oncologia Medica   (Italy)

Author keywords

5 fluorouracil; Breast cancer; Metastatic disease; Paclitaxel; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; NAVELBINE; PACLITAXEL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; VINBLASTINE;

AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; FEVER; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; PRIORITY JOURNAL; SKIN MANIFESTATION; THROMBOCYTOPENIA; ADULT; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 20144379904     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602335     Document Type: Article

References (28)

1. Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P, Piccart MJ (2003) EORTC Breast Cancer and Early Clinical Studies Groups: clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39: 2439-2449
2. Ballestrero A, Montemurro F, Gonella R, Capaldi A, Danova M, Friedman D, Puglisi M, Aglietta M, Patrone F (2003) Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability. Breast Cancer Res Treat 82: 185-190
3. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L (2000) Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 18: 3370-3377
4. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, Kreis W (2000) Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 18: 695-701
5. Cameron DA, Gabra H, Leonard RC (1994) Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70: 120-124
6. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66
7. Crown J, Dieras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, Marty M, Misset JL, Osterwalder B, Piccart M (2002) Chemotherapy for metastatic breast cancer - report of a European expert panel. Lancet Oncol 3: 719-726
8. Culine S, Roch I, Pinguet F, Romieu G, Bressolle F (1999) Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int J Oncol 14: 999-1006
9. Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB (1999) Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent figrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients. J Clin Oncol 17: 1407-1412
10. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN (2001) Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6: 133-146
11. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP, Meininger V (1989) Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16(Suppl 4): S9-S14
12. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN (2001) Phase I study of vinorelbine and paclitaxel by 3-h simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 91: 664-671
13. Knick V, Eberweis D, Miller CG (1995) Vinorelbine tartrate and paclitaxel combination: enhanced activity against in vivo p388 murine leukemia cells. J Natl Cancer Inst 87: 1072-1077
14. Kramer JA, Curran D, Piccart M, de Haes JCJM, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36: 1498-1506
15. Manfredi JJ, Horwitz SB (1984) Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-125
16. Martin M, Casado A, Perez Segura P, Garcia Carbonero I, Diaz-Rubio E (1998) Paclitaxel plus vinorelbine in metastatic breast cancer with contraindications to receive anthracyclines. Oncology 12(Suppl 1): S28-S30
17. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
18. Negri E, La Vecchia C, Decarli A (2001) Cancer mortality in Italy, 1997: quantifying the fall in rates in women and men. Tumori 87: 290-298
19. Photiou A, Shah P, Leong LK, Moss J, Retsas S (1997) In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines. Eur J Cancer 33: 463-470
20. Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A (1996) Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 7: 807-813
21. Romero Acuna L, Langhi M, Perez J, Romero Acuna J, Machiavelli M, Lacava J, Vallejo C, Romero A, Fasce H, Ortiz E, Grasso S, Amato S, Rodriguez R, Barbieri M, Leone B (1999) Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 17: 74-81
22. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-h paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361
23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
24. Therasse P, Arbruck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
25. Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, Citarella A, Carola M, Marzano N, Iaffaioli RV (1998) Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47: 91-97
26. Venturini M (2002) Rational development of capecitabine. Eur J Cancer 38(Suppl 2): S3-S9
27. Vici P, Amodio A, Di Lauro L, Conti F, Gionfra T, Belli F, Lopez M (2000) First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 58: 3-7
28. Vredenburgh J, Fishman R, Coniglio D, Matters L, Elkordy M, Ross M, Hussein A, Rubin P, Gilbert C, Petros W, Peters WP (1998) The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer. Am J Clin Oncol 21: 543-547